Abstract
Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.
| Original language | English (US) |
|---|---|
| Article number | 67 |
| Journal | Frontiers in Oncology |
| Volume | 5 |
| Issue number | APR |
| DOIs | |
| State | Published - 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- Metastatic
- Non-clear cell
- Renal cell carcinoma
- Targeted agents
- Treatment
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Metastatic non-clear cell renal cell carcinoma : An evidence based review of current treatment strategies. / Sankin, Alexander I.; Hakimi, A. Ari; Hsieh, James J.; Molina, Ana M.
In: Frontiers in Oncology, Vol. 5, No. APR, 67, 2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metastatic non-clear cell renal cell carcinoma
T2 - An evidence based review of current treatment strategies
AU - Sankin, Alexander I.
AU - Hakimi, A. Ari
AU - Hsieh, James J.
AU - Molina, Ana M.
PY - 2015
Y1 - 2015
N2 - Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.
AB - Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.
KW - Metastatic
KW - Non-clear cell
KW - Renal cell carcinoma
KW - Targeted agents
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84934293960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934293960&partnerID=8YFLogxK
U2 - 10.3389/fonc.2015.00067
DO - 10.3389/fonc.2015.00067
M3 - Article
AN - SCOPUS:84934293960
VL - 5
JO - Frontiers in Oncology
JF - Frontiers in Oncology
SN - 2234-943X
IS - APR
M1 - 67
ER -